Latest news with #Nona
Eater
3 days ago
- Business
- Eater
Broadacres Marketplace Reopens After Shuttering Over Immigration Fears
The sprawling open-air market in North Las Vegas went quiet, citing safety concerns within the local immigrant community amid a wave of federal immigration raids. At the time of closing, a spokesperson for the market said the decision was made 'out of an abundance of caution and concern' for its vendors, customers, and staff, many of whom are immigrants or second-generation U.S. citizens with family members who are immigrants. The shutdown displaced more than 1,100 small businesses — including food vendors like Birria de Res Zacatecas, Pupuseria El Cordero, and Las Enchiladas de Mama, who sell everything from handmade pupusas and birria tacos to mango chamoy snacks. The abrupt halt highlighted the deep unease rippling through immigrant communities as U.S. Immigration and Customs Enforcement (ICE) steps up operations in Nevada. Since 1977, the 45-acre marketplace has served the communities of North Las Vegas — where the population is 41 percent Latino residents, according to 2024 Census data — and the larger Southern Nevada community. The doors will open at 4 p.m. on Friday and opening weekend will be marked by family-friendly activities, kids' attractions, and a food fair with restaurant and snack vendors. Broadacres announced the reopening on Instagram and several vendors and customers commented with both excitement and trepidation — calling for clearer guidance on what steps are being taken to protect the community. Representatives from Broadacres Marketplace did not respond to a request for comment. Backstreet's Back … as shrunken heads The Golden Tiki The Golden Tiki Following their larger-than-life shows at the Sphere, the Backstreet Boys made a semi-secret appearance at the Golden Tiki. The preeminent Chinatown bar presented Nick Carter, Brian Littrell, and AJ McLean with custom shrunken heads — the latest additions to a collection that includes Bryan Cranston, Randy Couture, Robin Leach, Rod Stewart, Siegfried & Roy, and more. Since opening in 2015, the Golden Tiki has debuted more than 250 heads. It celebrates its 10th anniversary in August. Nona's Lobster Shack pops up at the Fontainebleau Fontainebleau Las Vegas is going all-in on New England summer with Nona's Lobster Shack, a new pop-up launching Saturday, August 2, inside Promenade Food Hall. The takeout menu includes lobster rolls with crab chips, New England clam chowder, shrimp cocktail, and sides like potato salad and coleslaw. There are also focaccia sandwiches filled with oven-roasted turkey, Italian tuna, fried chicken, and classic Italian deli meats. The shack will be open from 11 a.m. to 4 p.m. Thursday through Sunday. Baja meets Vegas in one-night-only dinner Sparrow + Wolf will host a special dinner on Sunday, August 3, with guest chefs David Castro Hussong and Maribel Aldaco Silva of Fauna — currently ranked number 17 on Latin America's 50 Best Restaurants. The one-night-only collaboration will blend Fauna's modern Mexican cuisine with chef Brian Howard's signature style. The $195 prix fixe meal includes Baja oysters, California halibut, heirloom corn, a variety of salsas, and more. Chef DJ Flores of Milpa and Nocturno is contributing yellow bolita corn from Oaxaca's Central Valley, and local grower Desert Moon is supplying lion's mane mushrooms. More details and reservations are available online. Eater Vegas All your essential food and restaurant intel delivered to you Email (required) Sign Up By submitting your email, you agree to our Terms and Privacy Notice . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Yahoo
12-06-2025
- Business
- Yahoo
Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases
CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced a license agreement with Visterra, Inc. to advance Visterra's next-generation biotherapeutic pipeline for immune-mediated and autoimmune diseases, leveraging Nona's proprietary HCAb Harbour Mice® technology platform. Nona's HCAb Harbour Mice® platform enables the generation of fully human heavy-chain-only antibodies (HCAbs), offering key advantages such as reduced immunogenicity and enhanced versatility for next-generation biotherapeutics. This innovative platform has been clinically validated and widely recognized by global partners. "We are pleased to collaborate with Visterra and support the development of their biotherapeutic pipeline," said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences. "This collaboration reflects our commitment to advancing biotherapeutic innovation. By leveraging our fully human HCAbs, we aim to unlock new therapeutic possibilities and accelerate the development of transformative medicines for patients worldwide." About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: About Visterra Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. For more information, please visit: View original content to download multimedia: SOURCE Nona Biosciences Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. MesoC2, originally developed using Nona's proprietary Harbour Mice® and integrated ADC platforms, was licensed to Pfizer in December 2023 under a global rights agreement. Pfizer is currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC). Poster Presentation at the 2025 ASCO Annual MeetingTitle: A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumorsAbstract Number: TPS3163Poster Board Number: 475aSession Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor BiologySession Date and Time: 02 June 2025; 1:30 PM-4:30 PM (CDT) Key Highlights from the Presentation: MesoC2 is an ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (TOP1i) payload (average drug-to-antibody ratio of 8). MesoC2 has shown potent antitumor efficacy in in vitro assays and xenograft models and an acceptable safety profile in cynomolgus monkeys. The Phase 1 trial (NCT06466187) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts. "We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies," said Dr. Jingsong Wang, Chairman of Nona Biosciences. "The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology." Pfizer's presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at (NCT06466187). About MesoC2 (HBM9033/PF-08052666) MesoC2 (HBM9033/PF-08052666) is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option. About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: View original content to download multimedia: SOURCE Nona Biosciences
Yahoo
23-05-2025
- Business
- Yahoo
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. MesoC2, originally developed using Nona's proprietary Harbour Mice® and integrated ADC platforms, was licensed to Pfizer in December 2023 under a global rights agreement. Pfizer is currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC). Poster Presentation at the 2025 ASCO Annual MeetingTitle: A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumorsAbstract Number: TPS3163Poster Board Number: 475aSession Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor BiologySession Date and Time: 02 June 2025; 1:30 PM-4:30 PM (CDT) Key Highlights from the Presentation: MesoC2 is an ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (TOP1i) payload (average drug-to-antibody ratio of 8). MesoC2 has shown potent antitumor efficacy in in vitro assays and xenograft models and an acceptable safety profile in cynomolgus monkeys. The Phase 1 trial (NCT06466187) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts. "We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies," said Dr. Jingsong Wang, Chairman of Nona Biosciences. "The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology." Pfizer's presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at (NCT06466187). About MesoC2 (HBM9033/PF-08052666) MesoC2 (HBM9033/PF-08052666) is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option. About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: View original content to download multimedia: SOURCE Nona Biosciences Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Rakyat Post
07-05-2025
- Business
- Rakyat Post
Pastry Entrepreneur Sues Younger Sisters And Brother RM1.5mil In Ultimate Sibling Rivalry
Subscribe to our FREE It's pretty normal for siblings to get into a tiff every now and then. It could be over a small thing such as who gets the front seat of the car when going on a car ride with mom and dad, or something a bit more serious such as reading another sibling's diary. But, what happens when there's bad blood over a business that cost probably hundreds of thousands in the making? That's what happened recently between four siblings, whose quarrel has escalated into a million-ringgit lawsuit. A pastry business owner claims she and her siblings were sued by their eldest sister Engku Putri Nadira Arshad, a co-owner of pastry outlet Eclairis, claimed on Instagram yesterday (6 May) that The Ordinary Baker, owned by her eldest sister Engku Putri Sharizad Arshad, is suing Eclairis for RM1.5 million. 'One of us made a decision that left the other three of us with no choice but to walk away. We didn't take a single cent. We just left. Quietly. 'And now we're being sued for RM1.5 million. It still hurts to say that out loud,' the caption wrote. The four siblings started The Ordinary Baker together in 2020 amidst the Covid-19 pandemic, and business was good. Throughout 2021, they operated out of their home, baking cream puffs and all sorts of pastries with whatever they could fit in their house. Come November 2021, they opened their first store in Setia Alam, which quickly went viral and was even featured on national television (RTM). Later in 2023, they expanded by opening another store in Shah Alam and went viral again, with local television channel TV3 featuring them on a segment of 'Nona'. The eldest sister claims she paid to set up the business, and settled her siblings' debts Meanwhile, according to a She claimed that the last of her investment into The Ordinary Baker was meant for a wedding cake business she wanted to set up for herself. 'I sacrificed my dream so they could have theirs. None of them contributed a single cent. But that's ok, after all OB was set up to help my family who at the time had no jobs,' she wrote in the caption. The entrepreneur then said the initial plan was to give the store's shares to her siblings but claimed that two of them were blacklisted. She then decided to delay putting their names on the company's shares until she settles their debts, which she claimed she did. She claimed that her siblings had accrued debts of up to RM100,000 which included money owed to TEKUN, a governmental small-to-medium enterprise (SME) development organisation, an education loan, loan sharks, and to her husband. 'Why is it important to clear your names before entering the company? For OB to grow, it needs financing, and financial institutions will do a background check – this is the reason their names are not there. I decided to go solo so it's easier for me to manage risks,' she said. The three siblings resigned after their eldest sister refused to open a third outlet In the same Facebook post, Sharizad accused her siblings of executing a coordinated attack on her by resigning with a 24-hour notice from the company on 1 November, 2024. She claimed to have no prior knowledge about it and ran the company single-handedly, hoping her siblings would return to work. However, they set up a new company two weeks after they left. The new business, Eclairis, allegedly used the same branding and recipes as The Ordinary Baker. According to her, this happened after she refused to open a third outlet just months after opening their first and second ones, explaining that the second store has not even reached its target return on investment (ROI). Amidst the chaos, she also highlighted the welfare of The Ordinary Baker's staff, who face risks such as retrenchment and paycuts, if she were forced to close one or all the outlets. Share your thoughts with us via TRP's . Get more stories like this to your inbox by signing up for our newsletter.
